Andere Sprachen Fulcrum Therapeutics, Inc.

Aktien

A2PM28

US3596161097

FULC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 30.04.2024			% 5 Tage	% 1. Jan.
7,13 ^USD	+0,71 %		-4,17 %	+5,63 %

18.03.	Fulcrum Therapeutics ernennt Patrick Horn zum Chief Medical Officer	MT
18.03.	Fulcrum Therapeutics, Inc. kündigt Änderungen in der Geschäftsführung an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium	28.03.
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	25.03.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	22.03.
Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	18.03.
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18.03.
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer	18.03.
Fulcrum Therapeutics, Inc. Announces Executive Changes	18.03.
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index	18.03.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08.03.
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	08.03.
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference	05.03.
GSK : la Dr Jeannie Lee entre au conseil d'administration	29.02.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	28.02.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27.02.
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27.02.
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023	27.02.
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET	20.02.
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06.02.
Fulcrum Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	08.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fulcrum Therapeutics, Inc.

Aktien

A2PM28

US3596161097

FULC

Andere Sprachen

Filter